Lumiracoxib
As of the edition of 20 October 2026, Lumiracoxib is a small molecule: marketed, first approved in 2003 (UK); acts on PTGS2.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2003
- Kind
- Small molecule
- First approved
- 12 September 2003 (UK)
- Approvals on record
- 1 in 1 region
- Holder of the most recent approval
- Novartis
- Withdrawn from market
- 1 January 2007 (in some regions)
- Registered trials
- 16, 1 stopped early
- Disease areas
- Bones, joints and muscles; Heart and blood vessels; Immune system; Pregnancy and women's health; Skin and connective tissue; Urinary and reproductive
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| PTGS2 | Prostaglandin G/H synthase 2 | P35354 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 2 | 1 | 0 | 0 | 1 |
| Phase 3 | 8 | 8 | 0 | 0 |
| Phase 4 | 7 | 7 | 0 | 0 |
| All trials | 16 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Novartis | Originator and Lead sponsor of trials | 2000 to now |